Application of combination of umbilical cord mesenchymal stem cells and algal polysaccharides in preparation of liver cirrhosis drugs
By combining umbilical cord mesenchymal stem cells with seaweed polysaccharides, the problem of insufficient efficacy and high cost of cirrhosis treatment is solved, and hepatitis reduction, fibrosis reversal and liver function recovery is achieved, which significantly improves the treatment effect and reduces side effects. and cost.
Patent Information
- Application Number
- CN202411105266.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
AI Technical Summary
The existing technology cannot effectively treat cirrhosis, especially in the end stage. Conventional treatment cannot be completely cured. There are high costs and donor shortages in liver transplantation, and although the efficacy of umbilical cord mesenchymal stem cells has been improved, it still needs to be further improved. Cure rates and reduce treatment costs.
Umbilical cord mesenchymal stem cells are used in combination with seaweed polysaccharides, which enhance immunity and promote cell viability by extracting specific seaweed polysaccharides such as Ulva polysaccharides, combined with tail vein injection of umbilical cord mesenchymal stem cells and oral seaweed polysaccharide treatment, enhance immunity and promote cell viability, and reverse liver fibers. Repair liver function.
Significantly alleviates hepatitis, reverses liver fibrosis, reduces liver dysfunction, improves liver function recovery rate, reduces toxic side effects, enhances efficacy and reduces treatment costs.
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to the application of umbilical cord mesenchymal stem cells combined with seaweed polysaccharides in the preparation of liver cirrhosis medicines. Background Art
[0002] Of the approximately 1.7 million patients worldwide with chronic liver disease, 25% to 30% develop severe fibrosis and eventually cirrhosis, resulting in hundreds of thousands of deaths worldwide each year. Currently, there is a lack of definitive treatments for cirrhosis, and patients often have a high dependency rate. Once liver function declines, accompanied by severe hypoproteinemia, the development of large amounts of refractory ascites in the abdominal cavity, and recurrent hepatic encephalopathy, these symptoms signal the end-stage of cirrhosis. Conventional treatments are ineffective at this stage, and liver transplantation is the only option for improving liver function. However, liver transplantation is currently expensive and donors are in short supply. Therefore, exogenous cell replacement therapy is a current research area. Umbilical cord mesenchymal stem cells (MSCs) have attracted considerable attention due to their widespread availability, ease of collection, and reduced immunogenicity compared to other MSC sources.
[0003] Seaweed polysaccharides are important biomacromolecules and the primary component of seaweed, accounting for over 50% of the dry weight of seaweed cells. Seaweed polysaccharides have a complex structure, composed of different monosaccharides linked by glycosidic bonds. Seaweed polysaccharides are diverse and can be categorized as red algae polysaccharides, green algae polysaccharides, and brown algae polysaccharides, depending on their algae source.
[0004] The chemical composition of different seaweed polysaccharides varies significantly depending on the seaweed species, growing season, and extraction and purification methods. Fucoidan, primarily derived from brown algae, is a complex marine sulfated polysaccharide composed primarily of fucose, galactose, mannose, and glucuronic acid, with small amounts of xylose, glucose, and glucosamine. It also possesses a unique sulfated L-fucose structure. Fucoidan exhibits numerous biological activities, including cell growth regulation, antiviral, and antioxidant properties.
[0005] At present, umbilical cord mesenchymal stem cells have a certain efficacy in treating end-stage liver cirrhosis. However, further improving the cure rate and survival rate of patients and reducing treatment costs are the directions of future treatment research. Summary of the Invention
[0006] The purpose of the present invention is to provide an application of umbilical cord mesenchymal stem cells combined with seaweed polysaccharides in the preparation of cirrhosis drugs. After combined use, the combined use can effectively improve hepatitis and cirrhosis symptoms with minimal toxic and side effects.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides the use of umbilical cord mesenchymal stem cells combined with seaweed polysaccharide in the preparation of a liver cirrhosis medicine.
[0009] Preferably, the seaweed polysaccharide is extracted from one or more large seaweeds selected from the group consisting of kelp, sargassum, undaria pinnatifida, ascophyllum, fucus, centipede, Eucheuma, Gracilaria, Gelidium, agar, Heterocarpus fulva, Enteromorpha and Ulva pertusa.
[0010] The umbilical cord mesenchymal stem cells combined with seaweed polysaccharides provided by the present invention can effectively reduce the degree of liver inflammation, reverse liver fibrosis, repair cirrhotic liver tissue, promote liver function recovery, and inhibit the formation of liver fibrosis, thereby being able to treat cirrhosis. Among them, seaweed polysaccharides can enhance human immunity and promote the activity or proliferation and differentiation of MSCs, thereby improving the therapeutic effect. DETAILED DESCRIPTION
[0011] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0012] Example 1
[0013] Umbilical cord mesenchymal stem cells were purchased from Beijing Han's United Biotechnology Co., Ltd. and added with physiological saline to adjust the concentration to 6×10 6 pcs / ml.
[0014] Extraction of seaweed polysaccharides
[0015] The Ulva pertusa was crushed and passed through a 40-mesh sieve. Distilled water 35 times its mass was added and extracted in a 135°C water bath for 5 hours. The algal residue was removed by passing through a 300-mesh sieve. The filtrate was dialyzed (dialysis bag with a molecular weight cut-off of 3500Da) for desalination for 48 hours and then concentrated under reduced pressure to 1 / 8 of the original volume. The product was precipitated with 3 times the volume of 95% ethanol for 36 hours and centrifuged at 5000rpm for 15 minutes. The precipitate was freeze-dried to obtain the Ulva pertusa polysaccharide for later use.
[0016] Experimental Example 1
[0017] Forty 6-week-old male SD rats (provided by the Animal Experiment Center of Southern Medical University) weighing 207-236 g were obtained.
[0018] Ten mice were randomly divided into four groups: Group 1 received only umbilical cord mesenchymal stem cells, Group 2 received only Ulva pertusa polysaccharide, and Group 3 received a combination of umbilical cord mesenchymal stem cells and Ulva pertusa polysaccharide. A control group received no medication. The animals were housed in separate cages and fed the same diet. All four groups were treated with carbon tetrachloride (CCl4) to establish a liver cirrhosis model.
[0019] CCl4 (40 ml / L, Sigma) was injected intraperitoneally at 0.2 ml / 100 g according to body weight, twice a week for 6 consecutive weeks to establish a cirrhosis model. One week after the last CCl4 injection, the following treatments were performed:
[0020] Group 1 was given 300 μl of the umbilical cord mesenchymal stem cells described in Example 1 via tail vein injection once a week;
[0021] The rats in group 2 were orally administered Ulva pertusa polysaccharide at a dose of 50 mg / kg, once every three days;
[0022] Group 3 received a weekly tail vein injection of 300 μl of umbilical cord mesenchymal stem cells and oral administration of Ulva pertusa polysaccharide every 3 days;
[0023] The control group was injected with 300 μl of normal saline via the tail vein;
[0024] Four weeks later, blood was collected from the orbital vein and the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using conventional methods, strictly following the kit procedures. The test results are shown in Table 1:
[0025] Table 1 Alanine aminotransferase and aspartate aminotransferase detection levels in each group
[0026] Group ALT activity (U / L) AST activity (U / L) 1 group 56.18±1.27 66.54±2.35 2 groups 73.24±2.04 82.35±2.14 3 groups 28.18±0.87 35.32±1.47 control group 129.04±3.24 189.32±1.1
[0027] The data in Table 1 show that both umbilical cord mesenchymal stem cells and Ulva pertusa polysaccharide can improve liver cirrhosis. However, the combination of umbilical cord mesenchymal stem cells and Ulva pertusa polysaccharide can more effectively reverse liver cirrhosis. Among them, the secretion levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) decreased, showing a trend towards the secretion levels of normal liver.
[0028] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. Application of umbilical cord mesenchymal stem cells combined with seaweed polysaccharides in the preparation of cirrhosis drugs.
2. The use according to claim 1, characterized in that: The seaweed polysaccharide is extracted from one or more large seaweeds selected from the group consisting of kelp, sargassum, undaria pinnatifida, ascophyllum, fucus, centipede, euchelonia, gracilaria, gracilaria, agar, hemerocallis, enteromorpha and Ulva pertusa.
